Open the gates: vascular neurocrine signaling mobilizes hematopoietic stem and progenitor cells

Tomer Itkin, … , Jesús María Gómez-Salinero, Shahin Rafii


Mobilization of hematopoietic stem and progenitor cells (HSPCs) from the bone marrow (BM) into the peripheral blood is a complex process that is enhanced dramatically under stress-induced conditions. A better understanding of how the mobilization process is regulated will likely facilitate the development of improved clinical protocols for stem cell harvesting and transplantation. In this issue of the JCI, Singh et al. (1) showed that the truncated cleaved form of neurotransmitter neuropeptide Y (NPY) actively promotes a breach of BM vascular sinusoidal portals, thereby augmenting HSPC trafficking to the circulation. The authors report a previously unrecognized axis, in which expression of the enzyme dipeptidylpeptidase-4 (DPP4)/CD26 by endothelial cells activates NPY-mediated signaling by increasing the bioavailability of the truncated form of NPY. These findings underscore the importance of and urgency to develop pharmacological therapies that target the vasculature and regulate diverse aspects of hematopoiesis, such as HSPC trafficking, in steady-state and stress-induced conditions.

Find the latest version:

http://jci.me/98323/pdf
Open the gates: vascular neurocrine signaling mobilizes hematopoietic stem and progenitor cells

Tomer Itkin, Jesús María Gómez-Salinero, and Shahin Rafii
Division of Regenerative Medicine, Ansary Stem Cell Institute, Department of Medicine, Weill Cornell Medicine, New York, New York, USA.

Mobilization of hematopoietic stem and progenitor cells (HSPCs) from the bone marrow (BM) into the peripheral blood is a complex process that is enhanced dramatically under stress-induced conditions. A better understanding of how the mobilization process is regulated will likely facilitate the development of improved clinical protocols for stem cell harvesting and transplantation. In this issue of the JCI, Singh et al. (1) showed that the truncated cleaved form of neurotransmitter neuropeptide Y (NPY) actively promotes a breach of BM vascular sinusoidal portals, thereby augmenting HSPC trafficking to the circulation. The authors report a previously unrecognized axis, in which expression of the enzyme dipeptidylpeptidase-4 (DPP4)/CD26 by endothelial cells activates NPY-mediated signaling by increasing the bioavailability of the truncated form of NPY. These findings underscore the importance of and urgency to develop pharmacological therapies that target the vasculature and regulate diverse aspects of hematopoiesis, such as HSPC trafficking, in steady-state and stress-induced conditions.

Overview of clinical hematopoietic stem and progenitor cell mobilization
The ability of hematopoietic stem and progenitor cells (HSPCs) to mobilize from the bone marrow (BM) is essential for the treatment of patients with hematological malignancies or disorders who undergo curative BM transplantation. For the past few decades, granulocyte CSF (G-CSF) has been the preferred mobilizing agent in clinical transplantation protocols (Figure 1); however, it is not fully clear how G-CSF induces stem cell mobilization or why certain individuals are resistant to G-CSF-mediated mobilization (2). Notably, approximately 10% of allogeneic donors and 40% of autologous donors fail to mobilize sufficient numbers of BM HSPCs to establish long-term engraftment (3), often resulting in aborted curative transplantation (4). Uncovering the pathways that modulate the mobilization of HSPCs could potentially offer a life-saving approach for the patients in need of a BM graft.

In response to G-CSF stimulation, recruitment of the CXCL12/CXCR4 signaling axis is one of the first steps for enhanced HSPC proliferation, motility, and egress into the peripheral blood (2, 5). Following G-CSF infusion, CXCL12 levels drop dramatically in BM (6) but increase in the circulation (7), possibly via endothelial re-secretion of scavenged CXCL12 (ref. 8 and Figure 1). Additionally, CXCR4 is upregulated by G-CSF in both murine and human HSPCs (6), further supporting the importance of the CXCL12/CXCR4 axis in HSPC mobilization. Notably, following circadian epinephrine secretion by the sympathetic nervous system, CXCL12 levels oscillate within the BM microenvironment, orchestrating steady-state egress (9). These findings highlight a regulatory role of the nervous system in the G-CSF-induced mobilization process.

Indeed, the sympathetic nervous system is pivotal for G-CSF-induced mobilization, as immature HSPCs express both dopaminergic and adrenergic receptors (10), which are further upregulated during G-CSF-induced mobilization. Moreover, mice with aberrant sympathetic nerve conduction are unable to downregulate CXCL12 in the BM and consequently fail to mobilize HSPCs in response to G-CSF (11). G-CSF treatment suppresses norepinephrine reuptake, thereby enhancing mobilized HSPCs (12). Therefore, oscillatory inputs from the nervous system during physiological HSPC trafficking and stressed-induced mobilization modulate BM cytokines and other putative proteolytic enzymes, thereby masterminding a balanced mobilization of HSPCs to the peripheral circulation (Figure 1).

Proteolytic activation of several factors is important during HSPC mobilization. Of note, CXCL12 mediates the release of soluble cleaved stem cell factor (SCF) via activation of MMP-9, resulting in enhanced HSPC egress from the BM (13). The membrane-bound type 1 MMP (MT1-MMP) is also expressed by HSPCs, upregulated following G-CSF stimulation, and actively participates in the HSPC mobilization process by cleaving the membrane-associated CD44 homing adhesion molecule (14). In addition, osteoclast-secreted cathepsin K (15) and the dipeptidylpeptidase 4 (DPP4, also known and herein referred to as CD26) (16) both cleave CXCL12 in vitro, which in turn may promote the degradation of CXCL12 in vivo. These data indicated a previously unappreciated role for proteolytic factors such as CD26 in HSPC mobilization.

Remarkably, G-CSF-induced mobilization of murine HSPCs is hampered by CD26 inhibition or in mice lacking CD26 (16, 17). CD26 cleaves a variety of proteins such as GM-CSF, G-CSF, IL-3, and erythropoietin that belong to the hematopoietic CSF family (18), deactivating further hematopoietic...

Related Article: p. 4527

Conflict of Interest: S. Rafii is a co-founder of and nonpaid consultant for Angiocrine Bioscience.
activity by the truncated cryptic forms of these proteins. Despite an increase in the binding affinity of truncated CSF proteins for their receptors (19), the truncated domains exhibited reduced CSF activity and negatively regulate hematopoiesis under stress-induced conditions (18), suggesting a possible regulatory negative feedback role for CD26 during G-CSF-induced mobilization. Additionally, CD26 is expressed by endothelial cells (ECs), and inhibition of CD26 maintains proper vascular barrier function during stress-induced conditions (20).

**BM vasculature regulation of HSPC trafficking**

Previous work demonstrated that trafficking of mature and immature hematopoietic cells is regulated by BM endothelial cells (BMECs) (21), suggesting the involvement of BMECs in successful BM transplantation procedures (22). ECs are first responders to stimulatory agents directing HSPC mobilization, as they express the sensory receptors for major participants in the mobilization process, including CXCR4 and β-adrenergic receptors (refs. 7, 8, and Figure 1).

BMECs respond to stimulus by actively relocating CXCL12 molecules from the abluminal side (BM parenchyma) to the lumen, which is in contact with the blood circulation (7, 8). A recent study ascertained a pivotal role for BM vascular permeability in regulating the activation and induction of HSPC motility (23).

All in vivo trafficking events of mature and immature hematopoietic cells are restricted primarily to the highly permeable sinusoidal blood vessels. Moreover, genetic or pharmacological disruption of proper vascular barrier function increases blood vessel permeability, boosts HSPC trafficking, and mobilizes HSPCs to the peripheral blood. Mechanistically, enhanced vascular fenestration allows higher penetration of blood plasma–carried factors, which in turn binds with higher affinity to NPYR2/5 (blue). Stimulation of NPY receptors triggers VE-cadherin (purple) internalization and degradation, enhancing BM vascular permeability. Increasing the permeability of the vascular barrier further promotes HSPC activation by enhancing intracellular HSPC ROS levels, HSPC motility, and the HSPC-expressed CXCR4 response to the CXCL12 gradient. Thus, the CD26/NPY/NPYR2/5 axis activates the vascular arm that favors the transendothelial migration of HSPCs into the peripheral blood. In the absence of CD26, NPY cryptic domain truncation is impaired, diminishing NPYR2/5 activation. As a consequence, in CD26-deficient mice, the vascular barrier retains the same steady-state permeability properties, preventing the full activation and translocation of BM HSPCs into the sinusoidal lumen.
Vascular neurocrine signals enhance blood-BM barrier permeability

In this issue, Singh et al. set out to decipher the mechanism by which CD26 relays G-CSF-induced HSPC mobilization (16, 17). This was achieved by performing sophisticated experiments to determine the extent to which CD26 expression by hematopoietic cells or by stromal cells in the BM microenvironment is essential for the stem cell mobilization process (1). Contrary to the prior hypothesis suggesting that CXCL12 cleavage by hematopoietic CD26 promotes HSPC migration out of the BM, Singh and colleagues showed that hematopoietic expression of CD26 is not essential for HSPC mobilization. Moreover, CD26 expression was reduced in mobilized HSPCs, and deletion of CD26 in murine HSPCs did not alter HSPC mobilization in a WT environment (1). These unexpected results align with recent reports indicating that CD26 truncates inflammatory cytokines into a nonactive form (18, 19) and, as such, may interfere with the hematopoietic response during alert and stress conditions. However, CD26 expression by niche cells was essential for proper HSPC mobilization (Figure 1).

Singh et al. observed that neither inhibition nor genetic deletion of CD26 had an effect on the properties of cells from any of the distinct subtypes of BM mesenchymal stromal cell lineages. Furthermore, ablation of CD26 activity failed to prevent a G-CSF-induced decrease in CXCL12 levels (1). Therefore, CD26 was not one of the in vivo enzymes responsible for CXCL12 degradation in the BM microenvironment.

Next, Singh and colleagues evaluated CD26 in the context of blood vessel ECs, which form a mechanical barrier between blood circulation and the inner marrow and regulate both BM stem cell homoeostasis and hematopoietic trafficking (23). CD26 expression was upregulated in a subtype of sinusoidal ECs, which represent an exclusive site for HSPC trafficking (23). Encouraged by evidence that CD26 supplied by endothelium promotes hematopoietic transendothelial migration in vitro, Singh et al. screened for a protein target for CD26 and identified the neurotransmitter neuropeptide Y (NPY) as a promising candidate for modulating HSPC mobilization (1). Like norepinephrine, NPY is a stress response element derived from the sympathetic nervous system and serves as a vasoconstrictor that orchestrates body metabolism and affects neuronal-mediating circadian rhythms (24).

Singh et al. confirmed that NPY was functionally truncated by CD26; moreover, the truncated form (NPY3-36) could enhance hematopoietic transendothelial migration. Sinusoidal ECs expressed the NPY receptors 2 and 5, which preferentially bound the truncated form of NPY, and administration of truncated NPY restored normal HSPC mobilization in CD26-deficient mice. In support of this proposition, truncated NPY also rescued the attenuated G-CSF–induced HSPC mobilization observed in NPY–/– mice (Figure 1 and ref. 1). Finally, truncated NPY augmented endothelial barrier permeability by downregulating adherent junction molecules, such as VE-cadherin and CD31. Enhanced sinusoidal permeability was determined by a gap widening between BM vascular ECs that resulted in greater penetration of blood-borne molecules into the BM parenchyma (1).

Conclusions

Singh et al. provide important insight into the complex mechanism that regulates stem cell mobilization by molecularly eavesdropping on the crosstalk among blood, bone, and brain elements (1). Previous studies have shown the importance of the CXCL12/CXCR4 axis in regulating HSPC mobilization as the immediate response to alarm or stress (2). Singh et al. mechanistically extended these observations by showing that this axis regulates only one arm of HSPC mobilization and requires the activation of additional arms to be effective. Induction of numerous early response factors during hematopoietic recovery facilitates the release of mobilizing factors from the sympathetic nervous system. Notably, norepinephrine promotes the activation of HSPCs and their release from the BM niche and augments enhanced motility via the CXCL12/CXCR4 axis. Yet, CD26 enables the activation of the truncated NPY, NPYR2/5 axis that further augments the trafficking of stimulated HSPCs through the primed BM sinusoidal portals. Further studies are warranted to uncover the connection between the neuronal system and vascular regulation and may involve examining the effect of the circadian tone over sinusoidal vascular portals, determining the precise source of NPY, and understanding the dynamic expression of CD26 and NPY receptors on distinct BM vascular beds in steady-state and stress hematopoiesis. The work by Singh et al. has opened the door for designing new, safer, and effective approaches to induce mobilization of HSPCs for curative therapies in patients who are refractory to current treatments.

Acknowledgments

The authors are supported by the Ansary Stem Cell Institute, the Starr Foundation Tri-Institutional Stem Cell Initiative, the Empire State Stem Cell Board, and New York State Department of Health grants, and by NIH R01 grants (DK095039, HL119872, HL128158, and HL115128) and U54 CA163167.

Address correspondence to: Shahin Rafii or Tomer Itkin, Weill Cornell Medicine, Department of Medicine, Division of Regenerative Medicine, Ansary Stem Cell Institute, 1300 York Avenue, New York, New York 10065, USA. Phone: 212.746.2070; Email: srafi@med.cornell.edu (S. Rafii). Phone: 212.746.4538; Email: toit2003@med.cornell.edu (T. Itkin).

References

and II-3 manifest distinct receptor-binding and regulatory functions compared with their full-length forms. *Leukemia*. 2017;31(11):2468–2478.


